NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Clarification. SurVaxM does have a phase 2b trial that started in November 2021 and intends to complete August 2024. NCT05163080
247 enrolled patients.

This is a triple blinded trial. However as you can see, they don’t merely want intended near total gross resection. They only want proven total or near total gross resection. This will also cause both arms (placebo and treatment) to have higher survival, (as it also did the single arm in the phase IIa study)

MRI within three days after surgery must show:

gross total resection consisting of no gadolinium enhancement; or b. near-total resection consisting of either = 1 cm3 nodular (i.e. volumetric) enhancement or = 100 mm2 in cross sectional area (i.e. linear enhancement).